Please use this identifier to cite or link to this item:
Full metadata record
|dc.contributor.author||Cebon, Jonathan S||en|
|dc.contributor.author||Andrews, Miles C||en|
|dc.identifier.citation||Journal of Clinical Pharmacy and Therapeutics 2014; 40(1): 121-3||en|
|dc.description.abstract||The management of metastatic melanoma has changed significantly in the past decade with the development of immunotherapies and targeted molecular therapies. Trials of targeted therapies have focused mainly on patients with the most common BRAF V600 mutations, namely V600E/K substitutions, with very little information available on the benefit of targeted therapies on less commonly occurring mutations such as V600R/D and M.We present a 54-year-old man with metastatic melanoma harbouring a rare BRAF V600M mutation, who experienced clinical and radiological response to combined therapy with the BRAF inhibitor dabrafenib and MEK inhibitor trametinib.As our understanding of these therapies evolves and an increasing number of patients have mutational testing performed, there is a clear imperative--as highlighted by this case--to test for rarer mutations and facilitate their inclusion both in everyday practice and in future clinical trials.||en|
|dc.title||Response to MAPK pathway inhibitors in BRAF V600M-mutated metastatic melanoma.||en|
|dc.identifier.journaltitle||Journal of clinical pharmacy and therapeutics||en|
|dc.identifier.affiliation||Joint Austin-Ludwig Medical Oncology Unit, Austin Health, Heidelberg, Vic., Australia||en|
|dc.identifier.affiliation||Ludwig Institute for Cancer Research - Austin Branch, Heidelberg, Vic., Australia||en|
|Appears in Collections:||Journal articles|
Files in This Item:
There are no files associated with this item.
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.